High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19.
bacteria
coronavirus
infections
pulmonary embolism
thrombosis
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
26
05
2022
accepted:
31
08
2022
entrez:
28
9
2022
pubmed:
29
9
2022
medline:
29
9
2022
Statut:
epublish
Résumé
This study's primary aim was to evaluate the impact of thrombotic complications on the development of secondary infections. The secondary aim was to compare the etiology of secondary infections in patients with and without thrombotic complications. This was a cohort study (NCT04318366) of coronavirus disease 2019 (COVID-19) patients hospitalized at IRCCS San Raffaele Hospital between February 25 and June 30, 2020. Incidence rates (IRs) were calculated by univariable Poisson regression as the number of cases per 1000 person-days of follow-up (PDFU) with 95% confidence intervals. The cumulative incidence functions of secondary infections according to thrombotic complications were compared with Gray's method accounting for competing risk of death. A multivariable Fine-Gray model was applied to assess factors associated with risk of secondary infections. Overall, 109/904 patients had 176 secondary infections (IR, 10.0; 95% CI, 8.8-11.5; per 1000-PDFU). The IRs of secondary infections among patients with or without thrombotic complications were 15.0 (95% CI, 10.7-21.0) and 9.3 (95% CI, 7.9-11.0) per 1000-PDFU, respectively ( In patients with COVID-19, thrombotic complications were associated with a high risk of secondary infections.
Sections du résumé
Background
UNASSIGNED
This study's primary aim was to evaluate the impact of thrombotic complications on the development of secondary infections. The secondary aim was to compare the etiology of secondary infections in patients with and without thrombotic complications.
Methods
UNASSIGNED
This was a cohort study (NCT04318366) of coronavirus disease 2019 (COVID-19) patients hospitalized at IRCCS San Raffaele Hospital between February 25 and June 30, 2020. Incidence rates (IRs) were calculated by univariable Poisson regression as the number of cases per 1000 person-days of follow-up (PDFU) with 95% confidence intervals. The cumulative incidence functions of secondary infections according to thrombotic complications were compared with Gray's method accounting for competing risk of death. A multivariable Fine-Gray model was applied to assess factors associated with risk of secondary infections.
Results
UNASSIGNED
Overall, 109/904 patients had 176 secondary infections (IR, 10.0; 95% CI, 8.8-11.5; per 1000-PDFU). The IRs of secondary infections among patients with or without thrombotic complications were 15.0 (95% CI, 10.7-21.0) and 9.3 (95% CI, 7.9-11.0) per 1000-PDFU, respectively (
Conclusions
UNASSIGNED
In patients with COVID-19, thrombotic complications were associated with a high risk of secondary infections.
Identifiants
pubmed: 36168552
doi: 10.1093/ofid/ofac454
pii: ofac454
pmc: PMC9511118
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofac454Investigateurs
Andrea Andolina
(A)
Alba Bigoloni
(A)
Simona Bossolasco
(S)
Elena Bruzzesi
(E)
Diana Canetti
(D)
Barbara Castiglioni
(B)
Massimo Cernuschi
(M)
Matteo Chiurlo
(M)
Paola Cinque
(P)
Raffaele Dell'Acqua
(R)
Liviana Della Torre
(L)
Nicola Gianotti
(N)
Monica Guffanti
(M)
Hamid Hasson
(H)
Emanuela Messina
(E)
Giulia Morsica
(G)
Silvia Nozza
(S)
Martina Ranzenigo
(M)
Caterina Uberti-Foppa
(C)
Concetta Vinci
(C)
Flavia Badalucco Ciotta
(F)
Martina Bottanelli
(M)
Tommaso Clemente
(T)
Ilaria Mainardi
(I)
Giovanni Mori
(G)
Rebecka Papaioannu Borjesson
(R)
Giacomo Ponta
(G)
Camilla Muccini
(C)
Andrea Mastrangelo
(A)
Chiara Oltolini
(C)
Vincenzo Spagnuolo
(V)
Luca Benassi
(L)
Giorgia Bigai
(G)
Enrica Bozzolo
(E)
Giorgia Borio
(G)
Cecilia Bussolari
(C)
Stefania Calvisi
(S)
Valentina Canti
(V)
Jacopo Castellani
(J)
Ludovica Cavallo
(L)
Marta Cilla
(M)
Elena Cinel
(E)
Nicola Compagnone
(N)
Teresa D'Aliberti
(T)
Sarah Damanti
(S)
Rebecca De Lorenzo
(R)
Giuseppe Di Lucca
(G)
Gaetano Di Terlizzi
(G)
Iulia Dumea
(I)
Federica Farolfi
(F)
Marica Ferrante
(M)
Claudia Frangi
(C)
Gabriele Gallina
(G)
Nicolò Germinario Bruno
(N)
Marco Lanzillotta
(M)
Raffaele Li Voti
(R)
Alessandro Marinosci
(A)
Sabina Martinenghi
(S)
Massimo Memoli
(M)
Marco Montagna
(M)
Maria Pascali
(M)
Alessandro Patrizi
(A)
Chiara Pomaranzi
(C)
Raffaella Scotti
(R)
Silvia Strada
(S)
Nicola Boffini
(N)
Giulio Cavalli
(G)
Emanuel Della Torre
(E)
Giacomo De Luca
(G)
Nicola Farina
(N)
Luca Moroni
(L)
Alvise Ramirez Giuseppe
(A)
Alessandro Tomelleri
(A)
Luisa Azzolini Maria
(L)
Martina Baiardo Redaelli
(M)
Grazia Calabrò Maria
(G)
Maria Casiraghi Giuseppina
(M)
Antonio Dell'Acqua
(A)
Stefano Fresilli
(S)
Francesca Guzzo
(F)
Giovanni Landoni
(G)
Gaetano Lombardi
(G)
Nicolò Maimeri
(N)
Elena Moizo
(E)
Giuseppe Nisi Francesco
(G)
Alessandro Oriani
(A)
Alessandro Ortalda
(A)
Nicola Pasculli
(N)
Marina Pieri
(M)
Stefano Turi
(S)
Luca Bertoglio
(L)
Victor Bilman
(V)
Silvia Carletti
(S)
Floriana Gona
(F)
Nicasio Mancini
(N)
Patrizia Della Valle
(P)
Chiara Molinari
(C)
Antonella Poloniato
(A)
Francesca Lalla
(F)
Dario Prestifilippo
(D)
Jacopo Sapienza
(J)
Federico Seghi
(F)
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. A.C. has received consultancy payments and speaking fees from Bristol-Myers Squibb, Gilead, ViiV Healthcare, Merck Sharp & Dohme, and Janssen-Cilag. All other authors declare that they have no conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
JAMA. 2020 Dec 22;324(24):2548-2549
pubmed: 33226423
J Thromb Thrombolysis. 2021 Apr;51(3):595-607
pubmed: 33586113
BMJ. 2020 Sep 4;370:m3379
pubmed: 32887691
Chest. 2021 Aug;160(2):454-465
pubmed: 33857475
J Am Heart Assoc. 2021 Feb 2;10(3):e019650
pubmed: 33228447
Lancet Haematol. 2020 Jun;7(6):e425
pubmed: 32470428
Clin Microbiol Infect. 2020 Dec;26(12):1622-1629
pubmed: 32711058
Pneumonia (Nathan). 2021 Apr 25;13(1):5
pubmed: 33894790
Front Immunol. 2019 Nov 05;10:2569
pubmed: 31749809
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
J Intensive Care. 2020 May 24;8:36
pubmed: 32483488
J Thromb Thrombolysis. 2021 Nov;52(4):999-1006
pubmed: 34047938
Phlebology. 2021 Jun;36(5):375-383
pubmed: 33241746
Lancet Infect Dis. 2021 Jun;21(6):e149-e162
pubmed: 33333012
Nat Med. 2021 May;27(5):904-916
pubmed: 33879890
BMJ. 2021 Feb 19;372:n487
pubmed: 33608304
Clin Infect Dis. 2021 Jun 15;72(12):e995-e1003
pubmed: 33216875
Clin Microbiol Infect. 2021 Mar;27(3):451-457
pubmed: 33223114
PLoS One. 2021 May 20;16(5):e0251966
pubmed: 34015018
Blood. 2020 Jul 23;136(4):381-383
pubmed: 32702124
Lancet Microbe. 2021 Aug;2(8):e354-e365
pubmed: 34100002
Clin Infect Dis. 2009 Jul 1;49(1):1-45
pubmed: 19489710
Chest. 2020 Sep;158(3):1143-1163
pubmed: 32502594
EClinicalMedicine. 2020 Dec;29:100639
pubmed: 33251499
Curr Opin Infect Dis. 2021 Aug 1;34(4):357-364
pubmed: 34039879
J Clin Invest. 2021 Jan 4;131(1):
pubmed: 33119547
J Cardiothorac Vasc Anesth. 2021 Dec;35(12):3631-3641
pubmed: 33518461
J Thromb Haemost. 2020 May;18(5):995-1008
pubmed: 31925863